China’s NMPA Proposes New Rules for Export Drug Manufacturing and Management
The National Medical Products Administration (NMPA) of China has issued a new set of regulations...
Policy / Regulatory
China’s CDE Seeks Public Comment on Latest Generic Drug Reference Preparations
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) is currently...
China’s CDE Releases Draft Guidelines for CAR-T Cell Therapy Clinical Trials
The Center for Drug Evaluation (CDE) in China has issued a draft proposal for “Technical...
China’s NMPA Launches Pilot Programs in Beijing and Shanghai for Innovative Drug Approvals
The National Medical Products Administration (NMPA) of China has given the green light to Beijing...
China’s State Council Unveils Guidelines to Enhance Basic Medical Insurance System
In a bid to address the evolving healthcare needs of an aging population and a...
US Lawmakers Probe Clinical Trials at Hospitals Linked to Chinese Military, Potential Impact on Pharma Industry
Reports from BioCentury and Endpoints News, based on anonymous insider sources, suggest that US lawmakers...
China’s Health Authorities Set Standards for Key Central Township Health Centers
The National Health Commission (NHC), National Disease Control and Prevention Administration, and National Administration of...
China’s State Council Unveils Five-Year Plan to Enhance Urbanization and Address “Three Rural Issues”
The State Council of China has released a “Five Year Action Plan for Deepening the...
Shanghai Aims to Become Capital Market Hub for High-Quality Science and Innovation Companies
The Shanghai municipal government has unveiled a comprehensive set of measures designed to enhance the...
NICE and AstraZeneca Fail to Reach Agreement on Enhertu Reimbursement for NHS
The UK’s National Institute for Health and Care Excellence (NICE) has announced that negotiations with...
Shanghai Unveils Comprehensive Measures to Strengthen Biopharmaceutical Industry
The Shanghai municipal government has issued a comprehensive set of measures aimed at bolstering the...
China’s NHSA and NHC to Integrate Village Clinics into Basic Medical Insurance System
The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC) of China have...
China’s NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs
In a meeting chaired by Party Secretary and Director of the National Medical Products Administration...
China’s NMPA Issues Guidelines for Onsite Inspections of Medical Device Companies
The National Medical Products Administration (NMPA) of China has released the “Guidelines for Onsite Inspection...
China’s H1 2024 Pharmaceutical Trade Data Indicates Mixed Performance in Global Markets
The Ministry of Industry and Information Technology (MIIT) has released a report on the first...
China’s NHC Reports 2023 County Hospital Medical Service Capability Evaluation Results
The National Health Commission (NHC) of China has released a notice detailing the results of...
Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement
Yipinhong Pharmacy Co., Ltd (SHE: 300723), a China-based pharmaceutical company, has made a significant repayment...
China Unveils Comprehensive 2030 Plan to Combat Diabetes
China’s National Health Commission (NHC), in collaboration with 12 other ministries, has unveiled the ‘Health...
NHSA Report: China’s Medical Insurance Fund Records Significant Growth and Savings in 2023
The National Healthcare Security Administration (NHSA) has released its comprehensive annual statistical report for the...
China’s NMPA Suspends Daewoong Bio’s Antibiotic, Excludes Firm from National Procurement Program
The National Medical Products Administration (NMPA) in China has taken a decisive step to suspend...